From Forgotten to Front Page: CMS Approves National Coverage for Tricuspid Valve Replacement
- maryrburrell
- Apr 3
- 1 min read
There was a time—not that long ago—when the tricuspid valve was known as the forgotten valve. If you had severe tricuspid regurgitation (TR), especially as a woman, you were often left without options, without hope… and without a voice.
I know, because I lived that reality. I was in hospice, praying for a miracle. That miracle came in the form of a new procedure—transcatheter tricuspid valve replacement (TTVR)—and a second chance at life with the EVOQUE system by Edwards Lifesciences.
Today, we got the news we’ve been waiting for: CMS has finalized its national coverage decision for TTVR! 🙌 That means Medicare patients across the country can now access this life-changing, non-surgical treatment for symptomatic tricuspid regurgitation.
This is so much more than a policy. It's validation. It's access. It’s a loud and clear message: You are not forgotten.
Read more here: 👉https://cardiovascularbusiness.com/topics/clinical/structural-heart-disease/cms-approves-medicare-coverage-transcatheter-tricuspid-valve-replacement
As someone who lived through being told there was “nothing more they could do,” I’m celebrating this victory for every patient still holding on to hope. It’s for the ones who’ve been dismissed, misdiagnosed, or made to feel invisible.❤️🩹🥑
Let’s keep shining a light on the tricuspid valve, and keep speaking from the heart, for the heart.
💬 Have you or someone you love been impacted by TR or valve disease? Let’s connect and share our stories—because they matter now more than ever.
Comments